Table 2.

Effects of intensive glycemic control, BP control, and fenofibrate on long-term kidney outcomes in 10,139 participants of the ACCORD study

OutcomeIntensive Glycemic ControlIntensive BP ControlFenofibrate Treatment
n=10,139 (5074 Intensive; 5065 Standard)n=4682 (2345 Intensive; 2337 Standard)n=5457 (2736 Fibrate; 2721 Placebo)
Event NumberUnivariable HR/SHR (95% CI)Multivariablea HR/SHR (95% CI)Event NumberUnivariable HR/SHR (95% CI)Multivariablea HR/SHR (95% CI)Event NumberUnivariable HR/SHR (95% CI)Multivariablea HR/SHR (95% CI)
Composite kidney outcome1652 Int 1759 Std0.92 (0.86 to 0.99)d0.92 (0.86 to 0.98)d780 Int 721 Std1.15 (1.04 to 1.23)d1.16 (1.05 to 1.28)d1007 Feno 903 Plac1.15 (1.05 to 1.26)d1.16 (1.06 to 1.27)d
Macroalbuminuriab,c421 Int 567 Std0.72 (0.64 to 0.82)d0.68 (0.59 to 0.77)d212 Int 219 Std1.00 (0.83 to 1.21)0.97 (0.79 to 1.17)304 Feno 253 Plac1.19 (1.00 to 1.40)1.11 (0.93 to 1.33)
Doubling of creatininec490 Int 464 Std1.05 (0.93 to 1.20)1.09 (0.94 to 1.23)245 Int 170 Std1.52 (1.25 to 1.85)d1.64 (1.30 to 2.06)d344 Feno 195 Plac1.83 (1.54 to 2.18)d2.00 (1.61 to 2.49)d
Dialysisc161 Int 190 Std0.84 (0.68 to 1.04)0.92 (0.72 to 1.16)72 Int 81 Std0.91 (0.67 to 1.25)0.90 (0.63 to 1.28)98 Feno 100 Plac0.97 (0.74 to 1.29)1.09 (0.80 to 1.50)
All-cause mortality952 Int 953 Std1.00 (0.92 to 1.09)1.00 (0.91 to 1.10)406 Int 403 Std1.03 (0.90 to 1.18)1.01 (0.88 to 1.17)537 Feno 559 Plac0.95 (0.84 to 1.06)0.96 (0.85 to 1.08)
  • ACCORD, Action to Control Cardiovascular Risk in Diabetes; HR, hazard ratio; SHR, subhazard ratio; 95% CI, 95% confidence interval; Int, intensive; Std, standard; Feno, fenofibrate; Plac, placebo.

  • a Multivariable analyses are adjusted for: baseline age, sex, ethnicity, study site, randomization to tight BP group, randomization to fenofibrate group, previous cardiovascular event, eGFR, urine albumin-to-creatinine ratio, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, hemoglobin A1c, and systolic BP.

  • b Denominators for macroalbuminuria outcome: 4410 intensive glycemic, 4431 standard glycemic; 2065 intensive BP, 2040 standard BP; 2388 fenofibrate, 2348 placebo.

  • c Models for nonfatal components of the composite outcome include death as a competing risk.

  • d Statistically significant results.